"The majority of my talk focused on describing differences in cancer-specific [survival] as well as overall survival," says Christine Ibilibor, MD.
In this video, Christine Ibilibor, MD, MSc, recaps her discussion at the 2023 ASCO Genitourinary Cancers Symposium titled, “Eliminating Differences in Outcomes by Race and Gender in Urothelial Carcinoma”. Ibilibor is an assistant professor at the University of Virginia in Charlottesville, VA.
Could you give an overview of your talk and some of the other topics that were discussed?
My topic was looking at ways and strategies for ameliorating some of the survival differences amongst men and women with urothelial carcinoma as well as amongst different racial groups. The majority of my talk focused on describing these differences in cancer-specific [survival] as well as overall survival. Then, discussing some of the ways that we can reduce these differences, either through patient-related, provider-[related], and system-related factors, with many of them also requiring the consideration of social determinants of health or the external environment that these patients find themselves in, as well as trying to promote decreases in delays to treatment [and] guideline-based care for these different groups.
What kind of disparities exist when it comes to urothelial carcinoma outcomes?
Unfortunately, women experience a worse overall cancer-specific survival, oftentimes, because they are diagnosed at more advanced stages at presentation. Amongst Black and African American patients, as well as Hispanic patients, they similarly have reduced survival long-term and are often diagnosed with more advanced tumors.
This transcription has been edited for clarity.